Profits from biological treatment in inflammatory bowel disease patients

Agnieszka Dobrowolska-Zachwieja; Ludwika Jakubowska-Burek

doi:10.5114/pg.2010.14033

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2010
vol. 5

Send email

Copy url:

abstract:

Review paper

Profits from biological treatment in inflammatory bowel disease patients

Agnieszka Dobrowolska-Zachwieja

,

Ludwika Jakubowska-Burek

Przegląd Gastroenterologiczny 2010; 5 (2): 68–76

DOI: https://doi.org/10.5114/pg.2010.14033

Online publish date: 2010/05/12

View full text Get citation

PlumX metrics:

Colitis ulcerosa (CU) and Crohn disease (CD) belong to inflammatory bowel diseases (IBD). Characteristic for the disease are remissions and recurrences, when the pharmacological treatment is necessery. Unfortunatelly, although there are instructions and the aims of treatment are precised, optimal therapeutic procedures are not well defined. Conventional methods are not effective in the most serious cases. In this paper standard therapuetic procedures and newest trends in treatment of IBD are described.

keywords:

Profits from biological treatment in inflammatory bowel disease patients

Agnieszka Dobrowolska-Zachwieja , Ludwika Jakubowska-Burek

inflammatory bowel diseases, biological treatment, therapeutic procedures in inflammatory bowel diseases

Agnieszka Dobrowolska-Zachwieja

,

Ludwika Jakubowska-Burek